Welcome to the 2020 Virtual Exhibitor Hub!
Here is your one-stop shop for all things 2020 exhibitors! Learn more about exhibiting companies, access their zoom rooms and find their representatives contact information below!
Virtual Exhibit Hall
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
Liz Djaraher - firstname.lastname@example.org
Christina Borkenhagen - email@example.com
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Tim Campbell – firstname.lastname@example.org
Julie Irvin – email@example.com
Anila Murshed – firstname.lastname@example.org
Shayne Solano -email@example.com
GSK is a science-led global healthcare company with a mission to help people. We research, manufacture, and make available a broad range of medicines, vaccines, and consumer healthcare products. Visit our websites for information about our products and resources.
BENLYSTA (belimumab) Website: BenlystaHCP.com
NUCALA (mepolizumab) Website: https://bit.ly/NUCALAHCP
If you are a Healthcare Professional registered to practice in the US and would like to connect with GSK Medical Affairs, please follow this link: https://www.gskusmedicalaffairs.com/
©2020 GSK or licensor.
BELBTHC200005 September 2020
Produced in USA
Anne Yatchenko - AYatchen@its.jnj.com
Pat McClain - PMcclain@its.jnj.com
Dana Griffith - DGriffi4@its.jnj.com
Sharon Gaston - SGaston@its.jnj.com
Peter Orrok - firstname.lastname@example.org
Click here to view the Janssen 2019 Transparency Report
In Season 2 of The Road to a Vaccine, host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic. Watch Season 2 of The Road to a Vaccine now.
Rich Carlson - Richard.email@example.com
Holly Vanhorn - firstname.lastname@example.org
Lauren Tassone - email@example.com
Sanofi, a global healthcare leader, discovers develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into three core global business units: Sanofi Genzyme, Sanofi Pasteur, and General Medicines. Consumer Healthcare is a standalone business unit.
© 2020 Sanofi and Regeneron Pharmaceuticals Inc. All Rights Reserved. MAT-US-2020381-v1.0-09/2020
Rachel Sollberger - firstname.lastname@example.org
Shyree Shepeard - email@example.com
Kara Panchik - firstname.lastname@example.org
Kirk Bonuito - email@example.com
Robert Thorpe - firstname.lastname@example.org
Shannon Coltrane - email@example.com
At UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 8,500 employees in 40 countries, we invest more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs.